Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
Common injection mistakes and how to avoid them Even experienced users make mistakes
Not for a week or two, but for months
And the cost of wasting a vial, per milligram, can be just as significant even though compounded tirzepatide costs less than brand-name options
Care beyond the first plan Month 3 is a checkpoint, not a finish line
Shed With a score of 9.2 out of 10, Shed ranks fifth for 2026 thanks to two features no other provider matches: medication format variety and a money-back guarantee